Vertex Pharmaceuticals VRTX
Vertex Pharmaceuticals is a US biopharmaceutical company that develops and commercializes innovative medicines, primarily for the treatment of cystic fibrosis, and is expanding its pipeline to other areas such as gene therapy and pain. Vertex maintains outstanding financial health (score 9.13) with net cash and operating margins of 38%, but its demanding valuation (P/E 30.68, EV/EBITDA 25.0) and 8% earnings growth limit the appeal at these prices.
Detailed metrics
Market and fundamental data as of the analysis date.
Full AI report
Generated automatically from the metrics, the macro context and the company's news.
Vertex Pharmaceuticals is a US biopharmaceutical company that develops and commercializes innovative medicines, primarily for the treatment of cystic fibrosis, and is expanding its pipeline to other areas such as gene therapy and pain. Vertex maintains outstanding financial health (score 9.13) with net cash and operating margins of 38%, but its demanding valuation (P/E 30.68, EV/EBITDA 25.0) and 8% earnings growth limit the appeal at these prices.
Score by category
| Category | Score |
|---|---|
| Financial health | 9.1 |
| Quality / Moat | 7.6 |
| Valuation | 3.6 |
| Growth | 6.5 |
| Dividend | 1.5 |
| Momentum | 7.4 |
| Risk & Context | 8.9 |
OVERALL SCORE: 6.6/10
Context and risks
No material exposure to the macro context: Vertex is not an energy producer, has no relevant debt and its biotech business does not depend on interest rates or oil prices. Geopolitical tech tensions do not apply to its model.
News considered in the analysis
- 2 Healthcare Stocks That Just Delivered Great News for Investors — Menciona Vertex como una de las dos acciones con buenas noticias, probablemente por su pipeline de dolor y enfermedad renal, pero sin detalles concretos.
- Maze Therapeutics (MAZE) Shares Moved, So What Is Driving Attention Now? — Ruido sobre una empresa distinta (Maze Therapeutics), sin impacto directo en Vertex.
- Vertex Pharmaceuticals (VRTX) Increases Despite Market Slip: Here's What You Need to Know — Noticia de movimiento de precios sin información fundamental nueva; el mercado ya lo ha descontado.
- Will Vertex's Kidney Disease Pipeline Be a New Growth Engine? — El pipeline de enfermedad renal (inaxaplin) es una oportunidad de crecimiento material, pero aún en fases clínicas avanzadas con riesgo de aprobación.
- Lilly’s latest China drug deal; Immunovant’s setback in lupus — Noticias sobre Lilly e Immunovant, sin impacto directo en Vertex.
Verdict: Hold; wait for a better entry after the recent 40% 12-month rally.
Main risk: The main risk is the dependence on its pain and kidney disease pipeline to sustain future growth, as the cystic fibrosis franchise is mature and approval of new drugs is not guaranteed.
Other Healthcare companies
Neighbours in the sector ranking, to compare without going back to the index.
See all 1,000+ companies in the index →